These noteworthy things happened in the beauty industry this week

·Peloreya is expected to create a new billion-level brand

·Huaxi Biotech's profit fell another 30% in the first half of the year

·Winona sold 2 billion yuan in the first half of the year

·Jinbo Biotech's performance in the first half of the year dropped double

·It was once acquired by 8 billion yuan, but now quietly withdraws from China

·125 million yuan was purchased and 6 million yuan was sold. This business lost 95%

financial report

Huaxi Biotech's profit fell another 30% in the first half of the year

On August 27, Huaxi Biotech announced its results for the first half of 2026: during the period, revenue was 1.756 billion yuan, down 22.32% year-on-year; net profit attributable to the parent was 153 million yuan, down 30.82% year-on-year; non-net profit attributable to the parent was 129 million yuan, down 25.49% year-on-year. This is the third consecutive year that Huaxi Bio has seen revenue and net profit double decline in the mid-term newspaper.

In terms of business, the performance of each line is significantly differentiated. The income from raw materials business was 638 million yuan, a year-on-year increase of 1.87%, accounting for 36.38% of the main business income; the income from medical terminal business was 599 million yuan, accounting for 34.15% of the main business income; the nutritional science innovation and transformation business increased by 59.71% year-on-year to 61 million yuan; The revenue from the former main skin science innovation and transformation business (original functional skin care products) was 448 million yuan, a year-on-year decrease of 50.88%, and its revenue share dropped to 25.53%.

While revenue is under pressure, the expense structure is being optimized. Huaxi Biotech's sales expenses decreased by 25.84% year-on-year, while the R & D expense ratio increased to 12.07%, an increase of 1.85 percentage points over the same period last year. Between this drop and the rise, Huaxi Biotech's intention to actively transform from scale expansion to quality growth is very obvious, reshaping long-term competitiveness by increasing investment in R & D and optimizing product structure.

The transformation will not be smooth sailing, but the direction is clear. Between the decline of established businesses and the cultivation of emerging sectors, it is not only time, but also the test of the market that needs to be crossed.

Winona sold 2 billion in the first half of the year

On August 24, Betany released its results for the first half of 2026: during the period, revenue was 2.592 billion yuan, a year-on-year increase of 9.27%; net profit attributable to the parent company was 292 million yuan, a year-on-year increase of 18.30%; net profit deducted from non-profit was 246 million yuan, a year-on-year increase of 34.85%.

In terms of brands, Winona's revenue in the first half of the year reached 1.999 billion yuan and has successfully gone to sea. Winona Baby's revenue was 169 million yuan, and Aikoman's revenue was 75.1383 million yuan. The year-on-year growth of these two brands exceeded 45%. It is estimated that Aikoman's annual revenue is expected to exceed 200 million yuan. Ji Rui Za's revenue was 259 million yuan, a year-on-year increase of more than 22%, and its annual revenue is expected to exceed 500 million yuan. Chupu's revenue in the first half of the year was 41.2392 million yuan, and it is expected to exceed 100 million yuan for the whole year.

In terms of channels, in the first half of the year, Betany's online channels achieved sales of 2.017 billion yuan, a year-on-year increase of 15.71%. OMO channel sales fell 18.74% year-on-year to 155 million yuan. Offline channel revenue fell 5.05% year-on-year to 403 million yuan.

Judging from the trend in the past five years, Betany's revenue will peak at 5.736 billion yuan in 2024, and its net profit will exceed 1 billion yuan in 2022. Although revenue fell slightly last year, it has rebounded to 2.592 billion yuan in the first half of this year. Overall, Betany is in a critical transition period to coordinated development of "multi-brand + strong scientific research + omni-channel". If the current growth rate continues in the second half of the year, annual revenue is expected to exceed 5.8 billion yuan, entering a new stage of development with more certainty and imagination.

Jinbo Biotech's performance in the first half of the year dropped double

On August 25, Jinbo Biotech released its 2026 semi-annual report: during the period, revenue was 771 million yuan, a year-on-year decrease of 10.2%; net profit attributable to the parent company was 281 million yuan, a year-on-year decrease of 28.2%. This is the second time that Jinbo Biotech has experienced a year-on-year decline in revenue and profits since the first half of 2020, moving from a period of explosive expansion to a stage of structural adjustment.

From a product perspective, the medical device sector is the main drag, with revenue decreasing by 15.95% year-on-year to 595 million yuan. Compared with the correction in the performance of medical devices, the report card of functional skin care products is even more eye-catching: revenue was 148 million yuan, a year-on-year increase of 22.93%, especially the revenue of single-ingredient functional skin care products increased by 95.51 percentage points year-on-year, reaching 37.0837 million yuan. If the current growth rate can be maintained, the annual revenue of functional skin care products is expected to exceed 300 million yuan, further consolidating its status as the "new engine of the company's growth".

Previously, relying on the "recombinant collagen" track dividend, Jinbo Biotech has piled its performance base to a higher level. Since the beginning of this year, competing products have been intensively listed and medical beauty terminal consumption has become more rational. Coupled with the company's initiative to optimize channel inventory and Strictly control accounts receivable, short-term financial data will inevitably be "painful".

brand

It was once acquired by 8 billion yuan, but now it has quietly withdrawn from China

Recently, L'Oréal's high-end cosmetics brand IT Cosmetics Tmall overseas flagship store announced that it would close its store and plans to voluntarily terminate its operations on September 2, 2026. It is worth noting that this store is the brand's only official online purchase channel in China, and there is no offline purchase channel yet.

IT Cosmetics was founded in 2008. Due to his own roseacne problem, founder Jamie Kern Lima teamed up with dermatologists to develop skin-nourishing cosmetics specifically for problem skin. In 2010, she sold more than 6000 concealers in 10 minutes during a live TV shopping broadcast, making her famous in the first battle. In 2016, L'Oréal acquired it for US$1.2 billion (approximately RMB 8.06 billion), setting a record for L'Oréal Group's largest acquisition in eight years at that time.

But L'Oréal's attempts to replicate the U.S. growth model into global markets have not gone smoothly. After the founder withdrew, the group successively made an impairment of 254.7 million euros and approximately 250 million euros on IT Cosmetics in 2021 and 2023. In the five years since entering China, IT Cosmetics has always operated in a purely online and cross-border mode, with no offline outlets, and has failed to establish deep connections with local consumers.

From a US$1.2 billion acquisition to two asset impairments, and now to its withdrawal from the China market, from L'Oréal's decision-making perspective, IT Cosmetics's departure is an active strategic contraction. After all, on L'Oréal China's chessboard, Helena, Lancome, and YSL are the few irreplaceable chess pieces.

125 million yuan was bought and 6 million yuan was sold. This business lost 95%

On August 24, LG LifeHealth announced that it would sell its 100% stake in Avon North America to Stratford Worldwide, an affiliate of global private equity firm Regent. The transaction amount is approximately US$6 million (approximately RMB 40.326 million) and is expected to be completed on September 1.

In January this year, Regent just acquired Avon International business from Natura & Co. After the completion of this acquisition, Avon North America and Avon International will return to the same ownership for the first time since the "separation" in 2016. Lisa Siders, current chief operating officer of Avon International, will serve as CEO of the combined group.

For LG Life and Health, this is more like a "parting". In 2019, LG LifeHealth acquired a 100% stake in Avon North America for US$125 million (approximately RMB 840 million), trying to use this as a springboard to expand the North American market. However, Avon North America continued to lose money after the acquisition, with revenue of 269.2 billion won (approximately RMB 1.31 billion) and a net loss of 30.1 billion won (approximately RMB 146 million) in 2025. The transaction price is only about 5% of the purchase price seven years ago, which is a typical "buy high and sell low." LG said the sale is for the North American market to focus on its own brand growth strategy.

In the beauty industry where the traditional direct sales model has declined, can Avon, which has ended its "separation", find a new rule of survival? The test has just begun.

This article explores Aromatherapy, fragrance, perfume, essential oil, non-fire aroma, aroma candle, rattan aroma, home aroma, natural aroma, diffuser, sharing the latest industry insights and offering practical references for enthusiasts.

Source: 品观网 (https://www.pinguan.com/)

This article is reproduced from the original source for information sharing only. If it infringes any copyright, please contact us and we will remove it promptly.

© 2026 CeresMall | www.CeresMall.com